Patent SG-11201407537Y-A (SG)
Title: Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
Inventor: BELVIN MARCIA
IPC: G01N33/48
Filed: 2013-06-07
Abstract: (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 12 December 2013 (12.12.2013) WIPOIPCT (10) International Publication Number WO 2013/182668 A1 (51) International Patent Classification: A61K39/00 (2006.01) A61K 45/06 (2006.01) A61K31/138 (2006.01) A61K 31/337 (2006.01) A61K 31/357 (2006.01) A61K31/4196 (2006.01) A61K31/4523 (2006.01) A61K31/513 (2006.01) A61K31/553 (2006.01) A61K31/555 (2006.01) A61K31/565 (2006.01) A61K31/573 (2006.01) A61K31/7068 (2006.01) CI20 1/68 (2006.01) G01N33/48 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/EP2013/061765 7 June 2013 (07.06.2013) English English (30) Priority Data: 61/657,484 61/808,727 8 June 2012 (08.06.2012) US 5 April 2013 (05.04.2013) US (71) Applicant (for all designated States except US): F. HOFF­ MANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH). (71) Applicant (for US only)-. GENENTECH, INC. [US/US]; 1 DNA Way, South San Francisco, California 94080 (US). (72) Inventors: BELVIN, Marcia; c/o Genentech, Inc., DNA 1 Way, South San Francisco, California 94080 (US). FRIEDMAN, Lori; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US). SAMPATH, Deepak; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US). WALLIN, Jeffrey; c/o Genentech, Inc., 1 DNA Way, South San Francisco, Cali­ fornia 94080 (US). (74) Agent: SAUER, Frank; Grenzacherstrasse 124, CH-4070 Basel (CH). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, [Continued on next page] (54) Title: MUTANT SELECTIVITY AND COMBINATIONS OF A PHOSPHOINOSITIDE 3 KINASE INHIBITOR COM­ POUND AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER O LU CN CO o Q O = FIG. 3B 10- 0.1 0.01 4* & — *\" •• PIK3CA PIK3CA WT Mutant PTFN PTEN/ Null PIK3CA (57) Abstract: Methods and compositions are provided for treating hyperproliferative disorders in patients with a PI3K inhibitor, GDC-0032 as a single agent or in combination with chemothera- peutic agents. WO 2013/182668 A1II III IIII lllll 111 Hill ill I I II11 III II11 III II III SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, — TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))